Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany.
Braitsch K, Schmalbrock LK, Jung P, Bumeder I, Kiewe P, Hecker JS, Verbeek M, Westermann J, Bullinger L, Keller U, Bassermann F, Krönke J, Götze KS, Rieger K. Braitsch K, et al. Among authors: schmalbrock lk. Hemasphere. 2022 Aug 9;6(9):e759. doi: 10.1097/HS9.0000000000000759. eCollection 2022 Sep. Hemasphere. 2022. PMID: 35966764 Free PMC article. No abstract available.
Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
Bill M, Jentzsch M, Bischof L, Kohlschmidt J, Grimm J, Schmalbrock LK, Backhaus D, Brauer D, Goldmann K, Franke GN, Vucinic V, Niederwieser D, Mims AS, Platzbecker U, Eisfeld AK, Schwind S. Bill M, et al. Among authors: schmalbrock lk. Blood Adv. 2023 Feb 14;7(3):436-444. doi: 10.1182/bloodadvances.2021005789. Blood Adv. 2023. PMID: 35381077 Free PMC article.
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.
Bohl SR, Schmalbrock LK, Bauhuf I, Meyer T, Dolnik A, Szyska M, Blätte TJ, Knödler S, Röhner L, Miller D, Kull M, Langer C, Döhner H, Letai A, Damm F, Heckl D, Bullinger L, Krönke J. Bohl SR, et al. Among authors: schmalbrock lk. Blood Adv. 2021 May 11;5(9):2391-2402. doi: 10.1182/bloodadvances.2020003541. Blood Adv. 2021. PMID: 33950175 Free PMC article.
Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study.
Thibeault C, Mühlemann B, Helbig ET, Mittermaier M, Lingscheid T, Tober-Lau P, Meyer-Arndt LA, Meiners L, Stubbemann P, Haenel SS, Bosquillon de Jarcy L, Lippert L, Pfeiffer M, Stegemann MS, Roehle R, Wiebach J, Hippenstiel S, Zoller T, Müller-Redetzky H, Uhrig A, Balzer F, von Kalle C, Suttorp N, Jones TC, Drosten C, Witzenrath M, Sander LE; Pa-COVID Study Group; Corman VM, Kurth F. Thibeault C, et al. Infection. 2021 Aug;49(4):703-714. doi: 10.1007/s15010-021-01594-w. Epub 2021 Apr 22. Infection. 2021. PMID: 33890243 Free PMC article.
Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
Schmalbrock LK, Dolnik A, Cocciardi S, Sträng E, Theis F, Jahn N, Panina E, Blätte TJ, Herzig J, Skambraks S, Rücker FG, Gaidzik VI, Paschka P, Fiedler W, Salih HR, Wulf G, Schroeder T, Lübbert M, Schlenk RF, Thol F, Heuser M, Larson RA, Ganser A, Stunnenberg HG, Minucci S, Stone RM, Bloomfield CD, Döhner H, Döhner K, Bullinger L. Schmalbrock LK, et al. Blood. 2021 Jun 3;137(22):3093-3104. doi: 10.1182/blood.2020007626. Blood. 2021. PMID: 33598693 Free PMC article. Clinical Trial.
getITD for FLT3-ITD-based MRD monitoring in AML.
Blätte TJ, Schmalbrock LK, Skambraks S, Lux S, Cocciardi S, Dolnik A, Döhner H, Döhner K, Bullinger L. Blätte TJ, et al. Among authors: schmalbrock lk. Leukemia. 2019 Oct;33(10):2535-2539. doi: 10.1038/s41375-019-0483-z. Epub 2019 May 14. Leukemia. 2019. PMID: 31089248 Free PMC article. No abstract available.
Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation.
Schmalbrock LK, Bonifacio L, Bill M, Jentzsch M, Schubert K, Grimm J, Cross M, Lange T, Vucinic V, Pönisch W, Behre G, Franke GN, Niederwieser D, Schwind S. Schmalbrock LK, et al. Bone Marrow Transplant. 2018 May;53(5):640-643. doi: 10.1038/s41409-017-0060-x. Epub 2018 Jan 15. Bone Marrow Transplant. 2018. PMID: 29335621 No abstract available.